We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
+34.63%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$208M
AUM Growth
-$246M
(-54%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-84.46%
Top 10 Holdings %
Top 10 Hldgs %
83.47%
Holding
151
New
27
Increased
12
Reduced
37
Closed
67
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HMTV
Hemisphere Media Group, Inc.
HMTV
|
+$9.46M |
| 2 |
Loop Industries
LOOP
|
+$2.38M |
| 3 |
TRNX
Taronis Technologies, Inc. Common Stock
TRNX
|
+$1.52M |
| 4 |
Novavax
NVAX
|
+$1.36M |
| 5 |
CODX
Co-Diagnostics
CODX
|
+$928K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$37.5M |
| 2 |
ESPR
Esperion Therapeutics
ESPR
|
+$6.39M |
| 3 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$4.97M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$4.47M |
| 5 |
Xeris Biopharma Holdings
XERS
|
+$3.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 10.57% |
| 2 | Materials | 0.95% |
| 3 | Consumer Discretionary | 0.9% |
| 4 | Technology | 0.61% |
| 5 | Industrials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CALL
Biogen
BIIB
$30.4B
| $54.4M | 26.15% |
2,303
+2,273
| +7,577% | +$716K |
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $50.2M | 24.1% |
1,776
-2,554
| -59% | -$694K |
|
3
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $33.9M | 16.3% |
2,216
-2,084
| -48% | -$251K |
|
4
PUT
CorMedix
CRMD
$577M
| $7.33M | 3.52% |
7,751
+7,690
| +12,607% | +$69.3K |
|
|
KYNB
5
PUT
Kyntra Bio
KYNB
$28.2M
| $5.95M | 2.86% |
44
+7
| +19% | +$9.49K |
|
|
6
CALL
iShares S&P 100 ETF
OEF
$19.8B
| $5.51M | 2.65% |
+360
| New | +$43.4K |
|
|
ODT
7
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $5.17M | 2.48% |
233,727
-284,398
| -55% | -$4.97M |
|
8
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $4.53M | 2.17% |
500
-2,719
| -84% | -$182K |
|
|
9
PUT
Biogen
BIIB
$30.4B
| $3.5M | 1.68% |
148
-1,115
| -88% | -$351K |
|
|
BCLI
10
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $3.23M | 1.55% |
49,680
-17,699
| -26% | -$1.01M |
|
|
AMRN
11
CALL
Amarin Corp
AMRN
$293M
| $3.07M | 1.48% |
74
-149
| -67% | -$53.7K |
|
12
Oramed Pharmaceuticals
ORMP
$171M
| $2.48M | 1.19% |
681,500
-251,550
| -27% | -$832K |
|
13
CALL
Wave Life Sciences
WVE
$1.13B
| $2.37M | 1.14% |
+610
| New | +$24.8K |
|
|
14
Loop Industries
LOOP
$35.6M
| $1.97M | 0.95% |
+248,436
| New | +$2.38M |
|
|
SOLO
15
DELISTED
Electrameccanica Vehicles Corp. Ltd.
SOLO
| $1.88M | 0.9% |
527,200
+327,200
| +164% | +$886K |
|
|
KYNB
16
CALL
Kyntra Bio
KYNB
$28.2M
| $1.83M | 0.88% |
+13
| New | +$17.6K |
|
|
17
Biogen
BIIB
$30.4B
| $1.66M | 0.8% |
7,000
-118,975
| -94% | -$37.5M |
|
|
PAVMZ
18
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
| $1.43M | 0.69% |
3,667,799
-255,405
| -7% | -$90K |
|
19
CALL
Ionis Pharmaceuticals
IONS
$9.14B
| $1.23M | 0.59% |
+1,848
| New | +$119K |
|
20
Genprex
GNPX
$4.05M
| $911K | 0.44% |
13
-6
| -32% | -$414K |
|
21
Cogent Biosciences
COGT
$6.95B
| $906K | 0.44% |
51,590
-60,114
| -54% | -$1.03M |
|
|
CODX
22
Co-Diagnostics
CODX
$5.2M
| $820K | 0.39% |
+25,778
| New | +$928K |
|
|
KYNB
23
Kyntra Bio
KYNB
$28.2M
| $717K | 0.34% |
528
-1,289
| -71% | -$1.75M |
|
|
ABIL
24
DELISTED
Ability Inc
ABIL
| $676K | 0.32% |
393,972
+35,998
| +10% | +$70K |
|
25
Microbot Medical
MBOT
$113M
| $646K | 0.31% |
83,333
-3,910
| -4% | -$30.4K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q1 2019 Portfolio in Review
As of Q1 2019, Sabby Management held 151 positions worth $208M, down 54% from $455M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Sabby Management withdrew a net $176M in Q1 2019, closing 67 positions and reducing 37 holdings. Its most notable exit was Esperion Therapeutics, an estimated $6.39M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 11% of assets, down from 21% a quarter earlier, followed by Materials and Consumer Discretionary.
Against the trend, Sabby Management opened a new position in Hemisphere Media Group, Inc. worth $113K.
- Sabby Management's largest Q1 2019 buy was Hemisphere Media Group, Inc.: 708,417 shares worth $113K.
- Sabby Management added most to OpGen, Inc in Q1 2019, an estimated $921K increase.
- Sabby Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $37.5M.
- Sabby Management fully exited Esperion Therapeutics in Q1 2019, selling an estimated $6.39M.
- Sabby Management's ten largest holdings make up 83% of its $208M portfolio in Q1 2019.
- Sabby Management opened 27 new positions and closed 67 in Q1 2019.
- Sabby Management's portfolio value fell 54% quarter-over-quarter to $208M.
Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.